Age- and Sex-Specific Prevalence and Incidence of Chronic Axonal Polyneuropathy in the General Population
Neuroepidemiology · 2026-11-09
DOI: 10.1159/ned/adwag063 ↗Abstract
Abstract Introduction: Robust epidemiological data are needed to better understand the burden of chronic axonal polyneuropathy. Since curative options for polyneuropathy are often lacking, focus on prevention is important. However, prevention requires a clear understanding of the population at risk and disease onset. This study aims to determine the prevalence and incidence of chronic axonal polyneuropathy in the general population. Methods: This study is part of the Rotterdam Study, an ongoing prospective population-based cohort study in the middle-aged and elderly population. The polyneuropathy screening consists of a symptom questionnaire, neurological examination, and nerve conduction study. Participants were screened at baseline from 2013 to 2017, and a follow-up screening was conducted from 2018 to 2024. Crude prevalence and incidence rate were obtained and age- and sex-specific as well as standardized prevalence and incidence rates were calculated. Results: Of 1894 eligible participants, aged 50 years and over, 113 had chronic axonal polyneuropathy at baseline (prevalence: 6.0%; 95% CI 4.9–7.1). During a median follow-up of 7.4 years, 48 new cases were identified over 12.708 person-years, resulting in an overall incidence rate of 3.8 (95% CI 2.8–5.0) per 1,000 person-years. Prevalence and incidence increased with age, and no statistically significant difference was found between males and females. Based on projections of the population’s age distribution, approximately a 19-24% increase in prevalence and a 39-52% increase in incidence of chronic axonal polyneuropathy is expected from 2025 to 2050. Conclusion: The observed prevalence and incidence, combined with the projected increase in the coming years based on aging of the population, emphasize the large and increasing number of especially elderly affected by and at risk of developing chronic axonal polyneuropathy. This highlights the need for more awareness in clinical practice and research into the etiology of chronic axonal polyneuropathy to enable prevention or delay progression of disease.
EUVIMED